Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.
The potential use of cannabidiol in the therapy of metabolic syndrome
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.
A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.
Is the cardiovascular system a therapeutic target for cannabidiol?
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.